**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 78527

**Manuscript Type:** MINIREVIEWS

**Histopathological assessment of the microscopic activity in inflammatory bowel diseases: What are we looking for?**

Fabian O *et al*. Assessing microscopic disease activity in IBD

Ondrej Fabian, Lukas Bajer

**Ondrej Fabian,** Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague 14021, Czech Republic

**Ondrej Fabian,** Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer Hospital, Prague 14059, Czech Republic

**Lukas Bajer,** Hepatogastroenterology Department, Institute for Clinical and Experimental Medicine, Prague 14021, Czech Republic

**Lukas Bajer,** Institute of Microbiology, Czech Academy of Sciences, Prague 14220, Czech Republic

**Author contributions:** Fabian O collected the data, performed the data analysis and wrote the paper; Bajer L participated in the data analysis and wrote the paper.

**Supported by** Ministry of Health of the Czech Republic, No. NV18-09-00493 and No. NU21J-06-00027.

**Corresponding author: Ondrej Fabian, MD, PhD, Assistant Professor, Postdoc,** Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, Prague 14021, Czech Republic. ondrej.fabian@ikem.cz

**Received:** July 1, 2022

**Revised:** August 11, 2022

**Accepted:** September 8, 2022

**Published online:** September 28, 2022

**Abstract**

Advances in diagnostics of inflammatory bowel diseases (IBD) and improved treatment strategies allowed the establishment of new therapeutic endpoints. Currently, it is desirable not only to cease clinical symptoms, but mainly to achieve endoscopic remission, a macroscopic normalization of the bowel mucosa. However, up to one-third of IBD patients in remission exhibit persisting microscopic activity of the disease. The evidence suggests a better predictive value of histology for the development of clinical complications such as clinical relapse, surgical intervention, need for therapy escalation, or development of colorectal cancer. The proper assessment of microscopic inflammatory activity thus became an important part of the overall histopathological evaluation of colonic biopsies and many histopathological scoring indices have been established. Nonetheless, a majority of them have not been validated and no scoring index became a part of the routine bioptic practice. This review summarizes a predictive value of microscopic disease activity assessment for the subsequent clinical course of IBD, describes the most commonly used scoring indices for Crohn's disease and ulcerative colitis, and comments on current limitations and unresolved issues.

**Key Words:** Crohn’s disease; Microscopy; Predictor; Score; Ulcerative colitis

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Fabian O, Bajer L. Histopathological assessment of the microscopic activity in inflammatory bowel diseases: What are we looking for? *World J Gastroenterol* 2022; 28(36): 5300-5312

**URL**: https://www.wjgnet.com/1007-9327/full/v28/i36/5300.htm

**DOI**: https://dx.doi.org/10.3748/wjg.v28.i36.5300

**Core Tip:** Approximately one third of the patients with inflammatory bowel diseases in endoscopic remission show persisting signs of microscopic disease activity. Histology seems to have a predictive value for development of severe clinical complications. Proper assessment of the microscopic activity of the disease using respective scoring indices is thus necessary. This review summarizes the most widely used histological scoring indices, discusses their advantages and limitations and comments persisting unresolved issues from the perspective of gastrointestinal pathologists.

**INTRODUCTION**

The first description of inflammatory bowel disease (IBD) dates back to 1932, when Burrill Bernard Crohn published the article "Regional ileitis: A pathologic and clinical entity"[1]. In the following decades, our understanding of IBD has evolved. Currently, we perceive both Crohn's disease (CD) and ulcerative colitis (UC) as systemic inflammatory conditions showing predilection to the gastrointestinal (GI) tract[2-4]. Despite persisting ominous etiology and poorly understood pathogenesis, substantial advances in diagnostics and therapy of IBD have been made, allowing new therapeutic endpoints to be laid out. At present, we strive not only to cease all clinical symptoms, but mainly to reach the endoscopic remission, defined as normalization of endoscopic mucosal appearance[5,6]. However, normal endoscopic finding does not necessarily reflect normal histology. Correlation between endoscopy and histology is poor and up to 1/3 of both CD and UC patients in endoscopic remission show signs of persisting histological activity[7-10]. There is increasing evidence that histological activity of the disease may be a better predictor of important clinical endpoints such as hospitalization rate, risk of clinical relapse, need for systemic corticosteroid use, or development of colorectal cancer when compared to sole endoscopy[11-16]. This is even more important for certain IBD subtypes such as IBD associated with primary sclerosing cholangitis, currently considered a distinct phenotype of IBD entailing a four times higher risk of a colorectal cancer development compared to conventional IBD[17,18]. The evaluation of the histological disease activity by reliable scoring indices thus represents an important part of the overall microscopic assessment. Nonetheless, a majority of them lack proper validation and none of them have been established in routine clinical practice. Endoscopy remains a gold standard for the assessment of luminal activity of the disease[5].

The aim of this review is to provide a summary of the most commonly used scoring indices for CD and UC, highlight clinical benefits of the microscopic disease activity assessment and comment on current limitations and unresolved issues from the pathologists’ perspective.

**BASIC PRINCIPLES OF IBD HISTOPATHOLOGY**

To better conceive microscopic features included in histopathological scoring indices, it seems convenient to briefly summarize a basic IBD pathology first. UC is characterized by a continuous inflammation affecting a rectum and progressing towards the proximal colon and terminal ileum. The inflammatory infiltrate is usually confined to the mucosa. Submucosa may be affected in case of severe colitis, but transmural inflammation is not a feature of UC. As far as CD is concerned, the inflammation displays a discontinuous pattern on both macroscopic and microscopic levels. Any part of the GI tract from the oral cavity to the anal region may be affected, while the terminal ileum is the most frequent site of the disease. The inflammation is typically transmural, infiltrating deeper layers of the bowel wall. In both IBD subtypes, the infiltrate is mainly mononuclear, with a predominance of lymphocytes and plasmacytes. The presence of neutrophils is a sign of the disease activity. In case of mildly active disease, they are scarce and confined to lamina propria. With an increasing degree of activity, they tend to infiltrate surface epithelium and colonic crypts (defined as cryptitis). Later on, the crypt walls are disrupted and neutrophils exudate into their lumina forming crypt abscesses. The most severe grade of activity is usually characterized by the presence of erosions and ulcerations. Erosions were traditionally defined as defects confined to the mucosa, whilst ulcerations penetrated deeper into the submucosa, but there is no strict adherence to this criterion in pathological practice. Currently, ulcerations are often recognized rather by the presence of granulation tissue and erosions by fibrinopurulent exudate covering the defect[4,19,20]. The inflammatory infiltrate is often accompanied by numerous eosinophils. However, their proper assessment remains challenging due to the lack of a clearly defined cut-off value for their pathological increase[21]. Their numbers also vary among bowel segments being more prevalent in the right-sided colon[22] and several studies document their substantial seasonal and geographic oscillation[23,24]. Other characteristic features of IBD are basal plasmacytosis and disrupted mucosal architecture. Basal plasmacytosis is defined as an increased number of plasmacytes between the base of the crypts and muscularis mucosae. It is a strong indicator of IBD and also one of the earliest signs of chronicity[25]. Disrupted mucosal architecture refers to any distortion of the physiological appearance of the crypts. Normally, colonic crypts are straight, parallel, and evenly spaced. In IBD, they show changes such as branching, angulation, dilatation, shortening, or dropout[26]. A hallmark of CD diagnosis is the presence of non-caseating epithelioid granulomas. Although a differential diagnosis of granulomatous colitis is broad, the presence of immune granuloma in IBD patients excludes the diagnosis of UC. Their incidence ranges from 15% to 85% according to various studies[26]. They are more closely tied to an ileocolic form of CD or CD with upper GI involvement[27] and seem to be almost twice as frequent in pediatric CD[28].

**A PREDICTIVE VALUE OF MICROSCOPIC DISEASE ACTIVITY FOR THE DEVELOPMENT OF CLINICAL COMPLICATIONS**

According to a recent meta-analysis by Gupta *et al*[8] performed on 2677 UC patients in endoscopic remission, the presence of persisting microscopic activity is associated with an increased risk of clinical relapse [odds ratio (OR) 2.41; 95% confidence interval (CI): 1.91-3.04]. These findings are supported by another meta-analysis by Yoon *et al*[29], which showed similar results based on the analysis of 757 UC patients in endoscopic remission. In their cohort, an absence of histological activity of the disease was associated with a 63% lower risk of clinical relapse (risk ratio 0.37; 95%CI: 0.24-0.56). In the study by Hefti *et al*[30], the authors evaluated 561 UC patients with a median follow-up of 21.4 years since the onset of the disease. According to both univariate and multivariate analyses, a mean histological inflammatory activity showed to be a significant predictor of colectomy (*P* < 0.001). Azad *et al*[31] showed that the presence of mucosal neutrophils and eosinophils in clinically and endoscopically quiescent UC was associated with an increased risk of clinical relapse over 12 mo (*P* < 0.01). Last but not least, Bryant *et al*[12] performed a study on 91 UC patients assessing a prognostic value of endoscopic and histological remission for the prediction of corticosteroid use, hospitalization and colectomy in a median 6-year follow-up. In their analysis, a histological remission was a predictor of colectomy and development of an acute severe colitis, in contrast to endoscopy (OR 0.42, 95%CI: 0.2-0.9, *P* = 0.02; OR 0.21, 95%CI: 0.1-0.7, *P* = 0.02 respectively). These results suggest that persisting histological activity of the disease seems to be associated with an adverse clinical course in UC patients.

Studies documenting a prognostic value of histology in CD are still limited in number. However, Christensen *et al*[14] demonstrated that the absence of histologic activity in patients with ileal CD is associated with a lower risk of clinical relapse [hazard ratio (HR) 2.05; 95%CI: 1.07-3.94; *P* = 0.031], corticosteroid use (HR 2.44; 95 % CI 1.17 - 5.09; *P* = 0.018) and medical escalation (HR 2.17; 95%CI: 1.2-3.96; *P* = 0.011) in a 21-mo follow-up. In the study by Brennan *et al*[32], the absence of histological activity was associated with a lower percentage of disease flares at both 12 mo (2.4% *vs* 25.5%, *P* = 0.03) and 24 mo (10.5% *vs* 37.8%, *P* = 0.05) of follow-up, in contrast to endoscopy, where no significant difference between an endoscopically active and an inactive disease was found. On the other hand, the aforementioned meta-analysis by Gupta *et al*[8], which analyzed the predictive value of histology in 2677 UC patients, did not confirm the results, which were displayed by the group of 129 CD patients.

A predictive value of histology for the development of colorectal dysplasia and cancer is of no less importance. A meta-analysis by Flores *et al*[33] performed on 1443 UC patients found that even isolated histologic activity in otherwise endoscopically normal mucosa increased the risk of neoplasia (OR 2.6, 95%CI: 1.49-4.46, *P* = 0.01). In the study by Gupta *et al*[16], the severity of histological inflammation correlated with the risk of progression to an advanced neoplasia (high-grade dysplasia, invasive cancer), with HR being 3.0 (95%CI: 1.4-6.3) for the mean inflammatory score, HR 3.4 (95%CI: 1.1-10.4) for the binary inflammatory score and HR 2.2 [inter-quartile range (IQR) 1.2-4.2] for the maximum inflammatory score. A case-control study of Rutter *et al*[34] included 68 patients with a colorectal neoplasia matched with 136 controls without a neoplasia revealed a highly significant correlation between the histological severity of inflammation and the risk of neoplasia development (OR 4.69, 95%CI: 2.10-10.48, *P* < 0.001). Pai *et al*[35] correlated 52 UC patients with colorectal cancer to 122 patients without cancer. Based on the retrospective re-evaluation of biopsies from the last five years, a mean histological disease activity assessed by two independent histological scores appeared to be a predictor of cancer development, in contrast to endoscopy (HR 7.53, 95%CI: 2.56-12.16, *P* < 0.001 and HR 5.89, 95%CI: 2.18-15.92, *P* < 0.001 respectively). In CD, the predictive value of histology for cancer development is still equivocal. However, in the study by Kirchgesner *et al*[36] assessing a cohort of 398 IBD patients including 237 patients with CD, mean histological disease severity was associated with the risk of cancer development (OR 1.69, 95%CI: 1.29-2.21, *P* < 0.001 per one-unit increase).

In summary, a vast majority of evidence suggests that cessation of microscopic inflammatory activity has a positive impact on the future clinical course of the disease, especially for patients suffering from UC. Assessment of the histological activity should therefore be an integral part of bioptic reports in all patients with IBD. However, the appropriate extent of the microscopic normalization is still not precisely established. In other words, we still lack a proper definition of histological remission. As a result, establishing it as a primary therapeutic endpoint in clinical practice or clinical trials still lacks validity[6,37,38].

**HISTOPATHOLOGIC SCORING INDICES FOR UC**

The first histopathological scoring index for UC and the first scoring index for IBD, in general, was established in the 1960s by Truelove and Richards[39]. Since then, up to thirty indices have been proposed according to Cochrane Collaboration review[40], although only a few of them have been fully validated. One of the most widely used remains the Geboes score (GS), established in 2000[41]. This score assesses seven histopathological features including architectural mucosal changes, chronic inflammatory infiltrate, neutrophils and eosinophils in lamina propria, intraepithelial neutrophils, crypt destruction, and mucosal defects. Each of the given variables is further subclassified according to its severity (Table 1). The overall microscopic inflammatory severity should be based on the worst score in the bioptic sample, not on the average grade counted from all samples. Although, such a score may appear overly complicated at the first glance (*i.e.*, grading of the cryptitis severity as < 5%, < 50%, and > 50% of the affected crypts in the sample), it showed surprisingly good interpersonal agreement in preliminary phases of the study, especially when evaluating the presence of disease activity and mucosal defects (Cohen's kappa coefficient κ was above 0.9). A weak agreement was reached for the assessment of an inactive chronic inflammation. The original purpose of the score was a classification scheme, intended to define specific thresholds of the inflammatory severity, such as the presence of the disease activity. In subsequent studies, the score was also used as a continuous scale, assessing treatment efficacy in clinical trials[42,43]. The score seems to have a decent predictive value, being a reliable predictor of a clinical relapse in patients in clinical and endoscopic remission[31,44]. However, it has not been completely validated. In 2017, the Geboes Simplified Score was proposed[45]. The score reduced grading of the inflammatory activity and included the presence of basal plasmacytosis (Table 2). The score shows better overall agreement compared to the original GS (κ 0.56 *vs* 0.4). With regards to individual grades, the best agreement was reached for the detection of the inflammatory activity (κ 0.7). However, the score has not yet been widely used.

Robarts histopathology index (RHI)[46] was established in 2017 and was primarily intended to assess microscopic changes induced by the treatment. The construction process of the index was based on the original GS, from which the histopathological variables with reliable interobserver agreement and good correlation with grades of the inflammatory activity according to Visual Analogue Scale were used and served as a foundation for the final index. The definitive index consists of four histopathological features including chronic inflammatory infiltrate, neutrophils in lamina propria, neutrophils in the epithelium and mucosal defects. Each of the features is further subclassified according to its severity (range 0 to 3), giving the final index range from 0 to 33 points (Table 3). In contrast to GS, RHI exclusively assesses the histologic activity of the disease and excludes the features of chronicity. The agreement among the index grades is very good, with an intraclass correlation coefficient above 0.8. A predictive value of the index is still not fully elucidated. However, the aforementioned study by Pai *et al*[35] showed that a mean index score ≥ 8 during 5 years of observation predicted the development of colorectal cancer.

In the same year, a Nancy histological index (NHI) was proposed[47,48]. It uses five-grade scale based on the presence of chronic and active inflammatory infiltrate and mucosal defects (Table 4 and Figure 1). The final grade is determined by the worst histopathologic feature found in a biopsy sample. Despite the subjective nature of some features making the thresholds between several grades prone to possible higher interobserver variability (*i.e.*, mild *vs* moderate intensity of the chronic inflammatory infiltrate defining grades 0 and 1 respectively), the index shows very good overall interobserver agreement (κ above 0.8) and also a good reciprocal correlation with RHI [49]. The score is fully validated and widely used in clinical practice. With regards to its predictive value, in the study of D'Amico *et al*[49] patients with histologic presence of the inflammation (NHI ≥ 1) had a higher risk of surgical intervention (14% *vs* 0%, *P* = 0.01) and hospitalization (36% *vs* 7.1%, *P* = 0.001) compared to patients in histological remission (NHI grade 0) during a 30-mo median follow-up.

**HISTOPATHOLOGIC SCORING INDICES FOR CD**

Scoring indices for CD are limited in number. The Cochrane collaboration review mentions 14 indices[50], but the only one used on the larger scale is the Global Histology Activity Score (GHAS)[51]. The score was established by D´Haens *et al* in 1998 with the purpose to assess early postoperative recurrence after ileocecal resection. It includes the following variables: the presence of architectural changes, degree of chronic, neutrophilic and eosinophilic inflammatory infiltration in lamina propria, presence of intraepithelial neutrophils, epithelial damage, mucosal defects, presence of granulomas, and a number of affected bowel segments (Table 5). Later on, the score became used separately for terminal ileum and large bowel as Ileal and Colonic GHAS[52]. However, the score is not validated and its utility is limited. Instead of being a continuous scale, it rather represents a sum of present variables, putting minute changes such as architectural distortion or increased mononuclear cells in lamina propria on the same level of importance, for instance mucosal defects. According to a recent multidisciplinary consensus panel[53], the score does not represent a reliable index for the assessment of the inflammatory severity in CD. Its eventual predictive value has not been evidenced.

**PRACTICAL ISSUES OF THE MICROSCOPIC ACTIVITY ASSESSMENT**

The sole fact that we have been regularly confronted with new indices indirectly implies that we are still struggling to find the perfect one that would satisfy all our demands. A lot of unresolved issues persist throughout the whole diagnostic process, reflecting both the proper biology of the disease and the limitations of given diagnostic modalities.

***Segmental and transmural character of the inflammation in CD***

A correlation between endoscopic and histologic activity in CD is poor due to the segmental nature of the inflammation on both macroscopic and microscopic levels. Indeed, some degree of discrepancy between endoscopy and histology is desirable since the histology should not only confirm the endoscopic findings but represent an additional value by increasing the sensitivity of the inflammatory activity detection. On the other hand, a focal character of the disease may lead to a false underestimation of the histological activity. It is especially true in patients on therapy since treated IBD typically shows a focal and patchy character of the inflammation, even in UC[54].

In CD, a transmural character of the inflammation is one of the defining features, modifying the overall clinical severity of the disease and eventual development of complications. However, both histology and endoscopy provide information exclusively about the luminal activity of the disease. There is thus an increasing effort to establish a reliable scoring index of transmural severity of the disease. The well-known Lemann index[55] represents a clinical score, assessing the cumulative damage of the intestinal wall according to the presence of strictures, penetrating disease (fistulas or abdominal abscesses), previous surgical interventions, and perianal involvement. The majority of histopathological indices of transmural involvement are aimed at the assessment of resection margins of ileocecal resections. Later on, more complex indices were established, evaluating a full spectrum of transmural CD pathology including a degree of inflammatory intensity, fibrosis, smooth muscle changes, or neuronal hypertrophy[56-58]. However, such scores cannot be applied to endoscopic bioptic samples. In some instances, the sample is so superficial, that the basal portion of the mucosa is missing, precluding the assessment of important predictors such as basal plasmacytosis, which is also included in some scoring indices such as Simplified GS.

***Upper GI and small intestinal involvement***

Both CD and UC are systemic inflammatory conditions capable of affecting any part of the GI tract. This is especially true for pediatric patients, in which the inflammation in the upper GI is more frequent. As defined by the revised Porto criteria for the diagnosis of IBD in children and adolescents[59], pediatric UC with upper GI involvement is even one of the atypical UC subtypes. However, grading of upper GI inflammatory severity is not a part of any available histological scoring index. In adult patients, a routine esophagogastroduodenoscopy is not even a part of the official recommendations for IBD diagnosis[2,3,59]. A subsequent clinical course may also be aggravated by the persisting inflammatory activity in a small bowel. However, an endoscopy can usually assess only its proximal and distal segments, frequently missing jejunum, and a large portion of the ileum. Key modalities for assessment the small bowel involvement are imaging techniques such as magnetic resonance imaging, computer tomography, ultrasonography or other radiologic procedures[60]. Some of them are also accompanied by respective scoring indices such as Simplified Magnetic Resonance Index of Activity for CD[61]. In recent years, scoring indices for capsule endoscopy were established, with Lewis Score[62] and Capsule Endoscopy Crohn Disease Activity Index[63] being among the most frequently used ones, recommended by both European Crohn’s and Colitis Organisation (ECCO) and European Society of Gastrointestinal Endoscopy. Currently, there is no feasible way to sample biopsies during capsule endoscopy.

***Number of bioptic samples***

According to an official recommendation from the European Society of Pathology and ECCO[4,5], a diagnostic endoscopy should include at least two bioptic samples from at least five or six bowel segments including the terminal ileum and rectum. However, there is still no official recommendation for patients on treatment. Many gastroenterologists still prefer to perform an extensive sampling of severely affected regions and avoid normally appearing segments. This may falsely underestimate an overall histological inflammatory severity and negatively affect some scoring indices such as GHAS, which includes the number of affected regions into a final score.

***Assessment of the disease activity in pediatric IBD***

A Histopathological scoring index primarily designated for the pediatric population has not been established. Adult indices are used instead, but their feasibility for children is not self-evident. Studies aiming at the predictive value of histology in pediatric IBD are still limited in number. A few years ago, our group performed a retrospective analysis of 63 children with CD[64]. The microscopic severity of the inflammation at the time of diagnosis assessed by GHAS showed moderate correlation with endoscopic activity evaluated by Simple Endoscopic Score for Crohn's Disease (*r* = 0.48, *P* = 0.0001), no correlation with clinical activity of the disease, and had no predictive value for the development of defined complications [bowel stricture, intraabdominal or perianal abscess or fistula, initiation of anti-tumor necrosis factor (anti-TNF) therapy] during at least one year of follow-up. On the other hand, endoscopic activity appeared to be a predictor of the complications (HR 3.20, IQR 1.04-4.91, *P* = 0.037). With regards to pediatric UC, our recently conducted retrospective study[65] including 49 children with UC showed that microscopic activity of the inflammation assessed by NHI and GS had no predictive value for complications development (acute severe colitis, need of colectomy, initiation of anti-TNF therapy, initiation of systemic 5-aminosalicylic therapy and systemic corticosteroid use). By contrast, levels of fecal calprotectin (FCPT) and clinical activity of the disease assessed by Pediatric Ulcerative Colitis Activity Index (PUCAI) showed to be independent predictors of the systemic 5-aminosalicylic acid induction (FCPT: HR 2.42, IQR 1.042-5.631, *P* = 0.040; PUCAI: HR 2.98, IQR 1.011-8.787, *P* = 0.048) and systemic corticosteroid use (FCPT: HR 2.517, IQR 1.115-5.681, *P* = 0.026; PUCAI: HR 2.98, IQR 1.011-8.787, *P* = 0.048).

**ARE WE ASKING THE RIGHT QUESTION?**

Histological activity in IBD is defined by the presence of neutrophils. Hence, strictly speaking, the histological index of the disease activity should be based on the extent of neutrophilic infiltration, their localization (lamina propria, superficial epithelium, cryptitis, crypt abscesses), and the presence of mucosal defects. Grading of the microscopic disease activity thus seems to be apparently straightforward. However, such grading per se is of no use if it does not provide any additional value to other means of disease activity assessment such as endoscopy or non-invasive biomarkers. There is thus a fundamental question about whether histological appearance is predictive of subsequent clinical outcomes. As mentioned before, the bulk of evidence suggests that persisting microscopic activity of the disease harbors an increased risk of development of complications. However, disease activity is not the only microscopic variable associated with an adverse clinical course. Other microscopic features such as basal plasmacytosis or granulomas have proven prognostic value. According to Johnson *et al*[66], the presence of granulomas was associated with increased serum levels of C-reactive protein, higher rates of stricturing and penetrating disease, higher rates of steroid, immunomodulators, biological therapy and narcotic use and higher healthcare utilization. With regards to basal plasmacytosis, the aforementioned meta-analysis by Gupta *et al*[8] demonstrated its predictive value for clinical recurrence in UC patients in endoscopic remission, as well. However, these features represent signs of chronicity rather than activity. Apart from that, there is still unresolved issue regarding the contribution of eosinophils, macrophages and other inflammatory cell types. Therefore, it seems to be more convenient to search for a suitable combination of microscopic features, providing the most accurate prediction for the subsequent clinical course of the disease, with a presence of neutrophils as a sign of the disease activity among the assessed variables. Apropos, the very presence of both chronic lymphoplasmacytic and active neutrophilic inflammatory infiltrate in one scoring index of disease activity may not properly reflect the biology of the process. In a majority of the scoring indices, the presence of isolated chronic inflammatory infiltrate is considered a lower grade of the inflammatory activity, aggravating with the increasing presence of neutrophils and eventually with the appearance of mucosal defects. But the lymphoplasmacytic infiltrate reflects rather chronicity of the process than its activity and these two variables don’t necessarily represent a continuum. Such a hypothesis was taken into consideration in the recently established scoring index called Inflammatory Bowel Disease-Distribution, Chronicity, Activity (IBD-DCA) score (Table 6)[67]. The score was proposed at Erlangen International Consensus Conference and consists of three parameters — Distribution (D), Chronicity (C) and, Activity (A), which are assessed in this order. Distribution determines the overall extent of the disease, independently of the presence or absence of the activity. Chronicity is represented by the disrupted mucosal architecture, presence of basal plasmacytosis and increased lymphoplasmacytic infiltration in lamina propria. Activity is marked by the presence of neutrophils. The score thus represents not only a scoring index of the histopathological inflammatory activity, but provides information about the overall microscopic severity of the disease. According to the recent evidence[68], it showed moderate inter-rater reliability for parameter D (median intraclass correlation coefficient 0.645), poor to moderate for parameter C (0.568), and moderate to good for parameter A (0.748) for UC and moderate to good for parameter D and A (0.655 and 0.644 respectively) and poor for parameter C (0.303) for CD. The intra-rater agreement was moderate to excellent for D and C parameters (0.894 and 0.798 respectively) and good to excellent for A (0.909) parameter for UC, whilst CD showed moderate to excellent agreement for parameter D (0.854), poor to excellent for parameter C (0.714) and good to excellent for parameter A (0.888). There is a moderate correlation with NHI and Simplified GS. The unique feature of the score is its versatility, which means that it can be used for both CD and UC, as well as for IBDU, which represents 5%-15% of both adult and pediatric IBD[69-71] and in some cases becomes a definite diagnosis. By this, the score questions the necessity of separate scoring indices for CD and UC. Both diseases share a similar pattern of inflammatory activity and the inferior utility of scoring indices for CD stems rather from the segmental and transmural nature of the disease that from inappropriate assessment of its histological activity. Such a hypothesis is also supported by several studies. In the aforementioned study of Kirchgesner *et al*[36] assessing a predictive value of histology for the development of colorectal cancer, the authors used NHI to evaluate microscopic disease severity for the whole IBD cohort. In both UC and CD, the grade of the NHI correlated with the risk of cancer development. In the study by Löwenberg *et al*[72], the authors evaluated the ability of vedolizumab to induce endoscopic and histological remission in patients with CD and the microscopic disease activity in the study was assessed by RHI. Using UC scoring indices for CD patients is suggested also by the recent expert consensus panel[53].

**STILL FAR FROM THE HISTOLOGICAL REMISSION**

Although achieving deeper mucosal healing is presumably associated with improved clinical course, it is far from synonymous with histological remission. However, establishing its proper definition remains challenging. In previous studies, the definition varied from the absence of active inflammation to the complete normalization of bowel mucosa. A recent position paper from ECCO defines histological remission as a "return to normal". Cessation of the microscopic activity undoubtedly correlates with a lower percentage of future complications. But even a mucosa without a presence of neutrophils may display increased chronic lymphoplasmacytic infiltration or architectonic changes that may aggravate the clinical course of the disease. Returning to the meta-analysis by Gupta *et al*[8] once more, their analysis showed that disrupted mucosal architecture was one of the features independently predicting the disease recurrence (OR 2.22). On the other hand, strict adherence to the histological normalization of the mucosa in each patient in endoscopic and clinical remission could lead to an unreasonable burden of aggressive therapy including all possible side effects. More studies need to be performed until a proper degree of histological normalization with an appropriate cost-benefit ratio will be established. One way or another, a complex histopathological scoring index assessing not only a disease activity but rather an overall microscopical severity seems to be necessary before we finally reach a standardized definition of the histological remission in IBD.

**CONCLUSION**

A proper assessment of the histological disease activity in IBD represents an essential component of the overall disease severity evaluation and provides important data for the subsequent clinical management of the patients. Many histopathological scoring indices exists, especially for UC, and they seem to be useful tools for the proper objectivization of the microscopic activity. However, their broader validation, subsequent implementation in routine bioptic practice and establishing the universally accepted definition of the histological remission are necessary before we could recognize the absence of the microscopic activity as the primary therapeutic target in IBD.

**ACKNOWLEDGEMENTS**

We would like to thank Drab D for his contribution during the manuscript revision.

**REFERENCES**

1 **Crohn BB**, Ginzburg L, Oppenheimer GD. Regional ileitis; a pathologic and clinical entity. *Am J Med* 1952; **13**: 583-590 [PMID: 12996536 DOI: 10.1016/0002-9343(52)90025-9]

2 **Magro F**, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F; European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. *J Crohns Colitis* 2017; **11**: 649-670 [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008]

3 **Gomollón F**, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. *J Crohns Colitis* 2017; **11**: 3-25 [PMID: 27660341 DOI: 10.1093/ecco-jcc/jjw168]

4 **Magro F**, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R; European Society of Pathology (ESP); European Crohn's and Colitis Organisation (ECCO). European consensus on the histopathology of inflammatory bowel disease. *J Crohns Colitis* 2013; **7**: 827-851 [PMID: 23870728 DOI: 10.1016/j.crohns.2013.06.001]

5 **Annese V**, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R; European Crohn's and Colitis Organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. *J Crohns Colitis* 2013; **7**: 982-1018 [PMID: 24184171 DOI: 10.1016/j.crohns.2013.09.016]

6 **Travis SP**, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O'Morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D'Haens G. Review article: defining remission in ulcerative colitis. *Aliment Pharmacol Ther* 2011; **34**: 113-124 [PMID: 21615435 DOI: 10.1111/j.1365-2036.2011.04701.x]

7 **Peyrin-Biroulet L**, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? *Clin Gastroenterol Hepatol* 2014; **12**: 929-34.e2 [PMID: 23911875 DOI: 10.1016/j.cgh.2013.07.022]

8 **Gupta A**, Yu A, Peyrin-Biroulet L, Ananthakrishnan AN. Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2021; **19**: 1800-1813.e4 [PMID: 33010406 DOI: 10.1016/j.cgh.2020.09.046]

9 **Chateau T**, Feakins R, Marchal-Bressenot A, Magro F, Danese S, Peyrin-Biroulet L. Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure. *Am J Gastroenterol* 2020; **115**: 179-189 [PMID: 31809296 DOI: 10.14309/ajg.0000000000000437]

10 **Molander P**, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. *J Crohns Colitis* 2013; **7**: 730-735 [PMID: 23182163 DOI: 10.1016/j.crohns.2012.10.018]

11 **Park S**, Abdi T, Gentry M, Laine L. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. *Am J Gastroenterol* 2016; **111**: 1692-1701 [PMID: 27725645 DOI: 10.1038/ajg.2016.418]

12 **Bryant RV**, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. *Gut* 2016; **65**: 408-414 [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598]

13 **Christensen B**, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. *Clin Gastroenterol Hepatol* 2017; **15**: 1557-1564.e1 [PMID: 28238954 DOI: 10.1016/j.cgh.2017.02.016]

14 **Christensen B**, Erlich J, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. *Clin Gastroenterol Hepatol* 2020; **18**: 2518-2525.e1 [PMID: 31812654 DOI: 10.1016/j.cgh.2019.11.056]

15 **Rubin DT**, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. *Clin Gastroenterol Hepatol* 2013; **11**: 1601-8.e1-4 [PMID: 23872237 DOI: 10.1016/j.cgh.2013.06.023]

16 **Gupta RB**, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. *Gastroenterology* 2007; **133**: 1099-105; quiz 1340-1 [PMID: 17919486 DOI: 10.1053/j.gastro.2007.08.001]

17 **Murasugi S**, Ito A, Omori T, Nakamura S, Tokushige K. Clinical Characterization of Ulcerative Colitis in Patients with Primary Sclerosing Cholangitis. *Gastroenterol Res Pract* 2020; **2020**: 7969628 [PMID: 33224192 DOI: 10.1155/2020/7969628]

18 **Soetikno RM**, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. *Gastrointest Endosc* 2002; **56**: 48-54 [PMID: 12085034 DOI: 10.1067/mge.2002.125367]

19 **Pai RK**, Lauwers GY, Pai RK. Measuring Histologic Activity in Inflammatory Bowel Disease: Why and How. *Adv Anat Pathol* 2022; **29**: 37-47 [PMID: 34879037 DOI: 10.1097/PAP.0000000000000326]

20 **Abraham C**, Cho JH. Inflammatory bowel disease. *N Engl J Med* 2009; **361**: 2066-2078 [PMID: 19923578 DOI: 10.1056/NEJMra0804647]

21 **Conner JR**, Kirsch R. The pathology and causes of tissue eosinophilia in the gastrointestinal tract. *Histopathology* 2017; **71**: 177-199 [PMID: 28370248 DOI: 10.1111/his.13228]

22 **Matsushita T**, Maruyama R, Ishikawa N, Harada Y, Araki A, Chen D, Tauchi-Nishi P, Yuki T, Kinoshita Y. The number and distribution of eosinophils in the adult human gastrointestinal tract: a study and comparison of racial and environmental factors. *Am J Surg Pathol* 2015; **39**: 521-527 [PMID: 25581733 DOI: 10.1097/PAS.0000000000000370]

23 **Polydorides AD**, Banner BF, Hannaway PJ, Yantiss RK. Evaluation of site-specific and seasonal variation in colonic mucosal eosinophils. *Hum Pathol* 2008; **39**: 832-836 [PMID: 18430454 DOI: 10.1016/j.humpath.2007.10.012]

24 **Pascal RR**, Gramlich TL, Parker KM, Gansler TS. Geographic variations in eosinophil concentration in normal colonic mucosa. *Mod Pathol* 1997; **10**: 363-365 [PMID: 9110299]

25 **Villanacci V**, Antonelli E, Reboldi G, Salemme M, Casella G, Bassotti G. Endoscopic biopsy samples of naïve "colitides" patients: role of basal plasmacytosis. *J Crohns Colitis* 2014; **8**: 1438-1443 [PMID: 24931895 DOI: 10.1016/j.crohns.2014.05.003]

26 **Moore M**, Feakins RM, Lauwers GY. Non-neoplastic colorectal disease biopsies: evaluation and differential diagnosis. *J Clin Pathol* 2020; **73**: 783-792 [PMID: 32737191 DOI: 10.1136/jclinpath-2020-206794]

27 **Freeman HJ**. Granuloma-positive Crohn's disease. *Can J Gastroenterol* 2007; **21**: 583-587 [PMID: 17853953 DOI: 10.1155/2007/917649]

28 **Rubio CA**, Orrego A, Nesi G, Finkel Y. Frequency of epithelioid granulomas in colonoscopic biopsy specimens from paediatric and adult patients with Crohn's colitis. *J Clin Pathol* 2007; **60**: 1268-1272 [PMID: 17293387 DOI: 10.1136/jcp.2006.045336]

29 **Yoon H**, Jangi S, Dulai PS, Boland BS, Prokop LJ, Jairath V, Feagan BG, Sandborn WJ, Singh S. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. *Gastroenterology* 2020; **159**: 1262-1275.e7 [PMID: 32585306 DOI: 10.1053/j.gastro.2020.06.043]

30 **Hefti MM**, Chessin DB, Harpaz NH, Steinhagen RM, Ullman TA. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. *Dis Colon Rectum* 2009; **52**: 193-197 [PMID: 19279411 DOI: 10.1007/DCR.0b013e31819ad456]

31 **Azad S**, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. *Saudi J Gastroenterol* 2011; **17**: 194-198 [PMID: 21546723 DOI: 10.4103/1319-3767.80383]

32 **Brennan GT**, Melton SD, Spechler SJ, Feagins LA. Clinical Implications of Histologic Abnormalities in Ileocolonic Biopsies of Patients With Crohn's Disease in Remission. *J Clin Gastroenterol* 2017; **51**: 43-48 [PMID: 26927490 DOI: 10.1097/MCG.0000000000000507]

33 **Flores BM**, O'Connor A, Moss AC. Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. *Gastrointest Endosc* 2017; **86**: 1006-1011.e8 [PMID: 28750838 DOI: 10.1016/j.gie.2017.07.028]

34 **Rutter M**, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. *Gastroenterology* 2004; **126**: 451-459 [PMID: 14762782 DOI: 10.1053/j.gastro.2003.11.010]

35 **Pai RK**, Hartman DJ, Leighton JA, Pasha SF, Rivers CR, Regueiro M, Binion DG, Pai RK. Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis. *J Crohns Colitis* 2021; **15**: 1481-1490 [PMID: 33687061 DOI: 10.1093/ecco-jcc/jjab042]

36 **Kirchgesner J**, Svrcek M, Le Gall G, Landman C, Dray X, Bourrier A, Nion-Larmurier I, Hoyeau N, Sokol H, Seksik P, Cosnes J, Fléjou JF, Beaugerie L; Saint-Antoine Inflammatory Bowel Disease Network. Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia. *Clin Gastroenterol Hepatol* 2020; **18**: 150-157.e1 [PMID: 31085339 DOI: 10.1016/j.cgh.2019.05.002]

37 **D'Haens G**, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. *Gastroenterology* 2007; **132**: 763-786 [PMID: 17258735 DOI: 10.1053/j.gastro.2006.12.038]

38 **Peyrin-Biroulet L**, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *Am J Gastroenterol* 2015; **110**: 1324-1338 [PMID: 26303131 DOI: 10.1038/ajg.2015.233]

39 **Truelove SC**, Richards WC. Biopsy studies in ulcerative colitis. *Br Med J* 1956; **1**: 1315-1318 [PMID: 13316140 DOI: 10.1136/bmj.1.4979.1315]

40 **Mosli MH**, Parker CE, Nelson SA, Baker KA, MacDonald JK, Zou GY, Feagan BG, Khanna R, Levesque BG, Jairath V. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. *Cochrane Database Syst Rev* 2017; **5**: CD011256 [PMID: 28542712 DOI: 10.1002/14651858.CD011256.pub2]

41 **Geboes K**, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. *Gut* 2000; **47**: 404-409 [PMID: 10940279 DOI: 10.1136/gut.47.3.404]

42 **Lemmens B**, Arijs I, Van Assche G, Sagaert X, Geboes K, Ferrante M, Rutgeerts P, Vermeire S, De Hertogh G. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. *Inflamm Bowel Dis* 2013; **19**: 1194-1201 [PMID: 23518809 DOI: 10.1097/MIB.0b013e318280e75f]

43 **Jairath V**, Peyrin-Biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-Bressenot A, Stitt LW, Shackelton LM, Khanna R, D'Haens GR, Sandborn WJ, Olson A, Feagan BG, Pai RK. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. *Gut* 2019; **68**: 1162-1168 [PMID: 30076171 DOI: 10.1136/gutjnl-2018-316702]

44 **Zenlea T**, Yee EU, Rosenberg L, Boyle M, Nanda KS, Wolf JL, Falchuk KR, Cheifetz AS, Goldsmith JD, Moss AC. Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. *Am J Gastroenterol* 2016; **111**: 685-690 [PMID: 26977756 DOI: 10.1038/ajg.2016.50]

45 **Jauregui-Amezaga A**, Geerits A, Das Y, Lemmens B, Sagaert X, Bessissow T, Lobatón T, Ferrante M, Van Assche G, Bisschops R, Geboes K, De Hertogh G, Vermeire S. A Simplified Geboes Score for Ulcerative Colitis. *J Crohns Colitis* 2017; **11**: 305-313 [PMID: 27571771 DOI: 10.1093/ecco-jcc/jjw154]

46 **Mosli MH**, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK, Frisbie V, Samaan MA, Jairath V, Driman DK, Geboes K, Valasek MA, Pai RK, Lauwers GY, Riddell R, Stitt LW, Levesque BG. Development and validation of a histological index for UC. *Gut* 2017; **66**: 50-58 [PMID: 26475633 DOI: 10.1136/gutjnl-2015-310393]

47 **Marchal-Bressenot A**, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S, Travis S, Peyrin-Biroulet L. Development and validation of the Nancy histological index for UC. *Gut* 2017; **66**: 43-49 [PMID: 26464414 DOI: 10.1136/gutjnl-2015-310187]

48 **Marchal-Bressenot A**, Scherl A, Salleron J, Peyrin-Biroulet L. A practical guide to assess the Nancy histological index for UC. *Gut* 2016; **65**: 1919-1920 [PMID: 27566129 DOI: 10.1136/gutjnl-2016-312722]

49 **D'Amico F**, Guillo L, Baumann C, Danese S, Peyrin-Biroulet L. Histological Disease Activity Measured by the Nancy Index Is Associated with Long-term Outcomes in Patients with Ulcerative Colitis. *J Crohns Colitis* 2021; **15**: 1631-1640 [PMID: 33822915 DOI: 10.1093/ecco-jcc/jjab063]

50 **Novak G**, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, D'Haens G, Jairath V, Khanna R. Histologic scoring indices for evaluation of disease activity in Crohn's disease. *Cochrane Database Syst Rev* 2017; **7**: CD012351 [PMID: 28731502 DOI: 10.1002/14651858.CD012351.pub2]

51 **D'Haens GR**, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. *Gastroenterology* 1998; **114**: 262-267 [PMID: 9453485 DOI: 10.1016/s0016-5085(98)70476-7]

52 **De Cruz P**, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn's disease: a systematic review. *Inflamm Bowel Dis* 2013; **19**: 429-444 [PMID: 22539420 DOI: 10.1002/ibd.22977]

53 **Almradi A**, Ma C, D'Haens GR, Sandborn WJ, Parker CE, Guizzetti L, Borralho Nunes P, De Hertogh G, Feakins RM, Khanna R, Lauwers GY, Mookhoek A, Pai RK, Peyrin-Biroulet L, Riddell R, Rosty C, Schaeffer DF, Valasek MA, Singh S, Crowley E, Feagan BG, Jairath V, Pai RK. An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. *Aliment Pharmacol Ther* 2021; **53**: 784-793 [PMID: 33410551 DOI: 10.1111/apt.16248]

54 **MATTS SG**. The value of rectal biopsy in the diagnosis of ulcerative colitis. *Q J Med* 1961; **30**: 393-407 [PMID: 14471445]

55 **Pariente B**, Mary JY, Danese S, Chowers Y, De Cruz P, D'Haens G, Loftus EV Jr, Louis E, Panés J, Schölmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, Fiorino G, Herzog M, Kamm MA, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, Tontini GE, Zagdanski AM, Bonifacio C, Rimola J, Nachury M, Leroy C, Sandborn W, Colombel JF, Cosnes J. Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. *Gastroenterology* 2015; **148**: 52-63.e3 [PMID: 25241327 DOI: 10.1053/j.gastro.2014.09.015]

56 **Schaeffer DF**, Walsh JC, Kirsch R, Waterman M, Silverberg MS, Riddell RH. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy. *Hum Pathol* 2014; **45**: 1928-1935 [PMID: 25022570 DOI: 10.1016/j.humpath.2014.05.016]

57 **Chen W**, Lu C, Hirota C, Iacucci M, Ghosh S, Gui X. Smooth Muscle Hyperplasia/Hypertrophy is the Most Prominent Histological Change in Crohn's Fibrostenosing Bowel Strictures: A Semiquantitative Analysis by Using a Novel Histological Grading Scheme. *J Crohns Colitis* 2017; **11**: 92-104 [PMID: 27364949 DOI: 10.1093/ecco-jcc/jjw126]

58 **Pennington L**, Hamilton SR, Bayless TM, Cameron JL. Surgical management of Crohn's disease. Influence of disease at margin of resection. *Ann Surg* 1980; **192**: 311-318 [PMID: 6998388 DOI: 10.1097/00000658-198009000-00006]

59 **Levine A**, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho KL, Veres G, Russell RK, Paerregaard A, Buderus S, Greer ML, Dias JA, Veereman-Wauters G, Lionetti P, Sladek M, Martin de Carpi J, Staiano A, Ruemmele FM, Wilson DC; European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. *J Pediatr Gastroenterol Nutr* 2014; **58**: 795-806 [PMID: 24231644 DOI: 10.1097/MPG.0000000000000239]

60 **Panes J**, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, Danese S, Halligan S, Marincek B, Matos C, Peyrin-Biroulet L, Rimola J, Rogler G, van Assche G, Ardizzone S, Ba-Ssalamah A, Bali MA, Bellini D, Biancone L, Castiglione F, Ehehalt R, Grassi R, Kucharzik T, Maccioni F, Maconi G, Magro F, Martín-Comín J, Morana G, Pendsé D, Sebastian S, Signore A, Tolan D, Tielbeek JA, Weishaupt D, Wiarda B, Laghi A. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. *J Crohns Colitis* 2013; **7**: 556-585 [PMID: 23583097 DOI: 10.1016/j.crohns.2013.02.020]

61 **Ordás I**, Rimola J, Alfaro I, Rodríguez S, Castro-Poceiro J, Ramírez-Morros A, Gallego M, Giner À, Barastegui R, Fernández-Clotet A, Masamunt M, Ricart E, Panés J. Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's Disease. *Gastroenterology* 2019; **157**: 432-439.e1 [PMID: 30953614 DOI: 10.1053/j.gastro.2019.03.051]

62 **Gralnek IM**, Defranchis R, Seidman E, Leighton JA, Legnani P, Lewis BS. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. *Aliment Pharmacol Ther* 2008; **27**: 146-154 [PMID: 17956598 DOI: 10.1111/j.1365-2036.2007.03556.x]

63 **Gal E**, Geller A, Fraser G, Levi Z, Niv Y. Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). *Dig Dis Sci* 2008; **53**: 1933-1937 [PMID: 18034304 DOI: 10.1007/s10620-007-0084-y]

64 **Fabian O**, Hradsky O, Potuznikova K, Kalfusova A, Krskova L, Hornofova L, Zamecnik J, Bronsky J. Low predictive value of histopathological scoring system for complications development in children with Crohn's disease. *Pathol Res Pract* 2017; **213**: 353-358 [PMID: 28216137 DOI: 10.1016/j.prp.2017.01.009]

65 **Fabian O**, Hradsky O, Lerchova T, Mikus F, Zamecnik J, Bronsky J. Limited clinical significance of tissue calprotectin levels in bowel mucosa for the prediction of complicated course of the disease in children with ulcerative colitis. *Pathol Res Pract* 2019; **215**: 152689 [PMID: 31679791 DOI: 10.1016/j.prp.2019.152689]

66 **Johnson CM**, Hartman DJ, Ramos-Rivers C, Rao BB, Bhattacharya A, Regueiro M, Schwartz M, Swoger J, Al Hashash J, Barrie A, Pfanner TP, Dunn M, Koutroubakis IE, Binion DG. Epithelioid Granulomas Associate With Increased Severity and Progression of Crohn's Disease, Based on 6-Year Follow-Up. *Clin Gastroenterol Hepatol* 2018; **16**: 900-907.e1 [PMID: 29277619 DOI: 10.1016/j.cgh.2017.12.034]

67 **Lang-Schwarz C**, Agaimy A, Atreya R, Becker C, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Tilg H, Villanacci V, Westerhoff M, Vieth M. Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. *Virchows Arch* 2021; **478**: 581-594 [PMID: 33373023 DOI: 10.1007/s00428-020-02982-7]

68 **Lang-Schwarz C**, Angeloni M, Agaimy A, Atreya R, Becker C, Dregelies T, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Siegmund B, Tilg H, Villanacci V, Westerhoff M, Ferrazzi F, Vieth M. Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn´s Disease. *J Crohns Colitis* 2021; **15**: 1621-1630 [PMID: 33773497 DOI: 10.1093/ecco-jcc/jjab055]

69 **Winter DA**, Karolewska-Bochenek K, Lazowska-Przeorek I, Lionetti P, Mearin ML, Chong SK, Roma-Giannikou E, Maly J, Kolho KL, Shaoul R, Staiano A, Damen GM, de Meij T, Hendriks D, George EK, Turner D, Escher JC; Paediatric IBD Porto Group of ESPGHAN. Pediatric IBD-unclassified Is Less Common than Previously Reported; Results of an 8-Year Audit of the EUROKIDS Registry. *Inflamm Bowel Dis* 2015; **21**: 2145-2153 [PMID: 26164665 DOI: 10.1097/MIB.0000000000000483]

70 **Rinawi F**, Assa A, Eliakim R, Mozer-Glassberg Y, Nachmias Friedler V, Niv Y, Rosenbach Y, Silbermintz A, Zevit N, Shamir R. The natural history of pediatric-onset IBD-unclassified and prediction of Crohn's disease reclassification: a 27-year study. *Scand J Gastroenterol* 2017; **52**: 558-563 [PMID: 28128677 DOI: 10.1080/00365521.2017.1282008]

71 **Guindi M**, Riddell RH. Indeterminate colitis. *J Clin Pathol* 2004; **57**: 1233-1244 [PMID: 15563659 DOI: 10.1136/jcp.2003.015214]

72 **Löwenberg M**, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, Hindryckx P, Rispens T, de Vries A, van der Woude CJ, Berends S, Ambarus CA, Mathot R, Clasquin E, Baert F, D'Haens G. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. *Gastroenterology* 2019; **157**: 997-1006.e6 [PMID: 31175865 DOI: 10.1053/j.gastro.2019.05.067]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 1, 2022

**First decision:** August 1, 2022

**Article in press:** September 8, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Czech Republic

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Iizuka M, Japan; Qian N, China **S-Editor:** Gao CC **L-Editor: P-Editor:** Gao CC

**Figure Legends**



**Figure 1 Microphotographs representing individual grades of Nancy Histopathological Index (hematoxylin and eosin, magnification 100×).** A: Grade 0 with no increase in inflammatory cells; B: Grade 0 with mild increase in chronic inflammatory cells; C: Grade 1 with moderate increase in chronic inflammatory cells including more numerous eosinophils, but no neutrophils; D: Grade 2 with scarce neutrophils in lamina propria and epithelium; E: Grade 3 with numerous neutrophils including cryptitis and crypt abscess; F: Grade 4 with completely ulcerated colonic mucosa replaced by granulation tissue.

**Table 1 Original Geboes score**

|  |  |
| --- | --- |
| **Original Geboes score** |  |
| Grade 0: Architectural changes | 0.0 No abnormality; 0.1 Mild abnormality; 0.2 Mild/moderate diffuse or multifocal abnormalities; 0.3 Severe diffuse or multifocal abnormalities |
| Grade 1: Chronic inflammatory infiltrate | 1.0 No increase; 1.1 Mild but unequivocal increase; 1.2 Moderate increase; 1.3 Marked increase |
| Grade 2A: Eosinophils in lamina propria | 2A.0 No increase; 2A.1 Mild but unequivocal increase; 2A.2 Moderate increase; 2A.3 Marked increase |
| Grade 2B: Neutrophils in lamina propria | 2B.0 No increase; 2B.1 Mild but unequivocal increase; 2B.2 Moderate increase; 2B.3 Marked increase |
| Grade 3: Neutrophils in epithelium | 3.0 None; 3.1 < 5% crypts involved; 3.2 < 50% crypts involved; 3.3 > 50% crypts involved |
| Grade 4: Crypt destruction | 4.0 None; 4.1 Probable: local excess of neutrophils in part of the crypts; 4.2 Probable: marked attenuation; 4.3 Unequivocal crypt destruction |
| Grade 5: Erosions and ulcerations | 5.0 No erosion, ulceration or granulation tissue; 5.1 Recovering epithelium + adjacent inflammation; 5.2 Probable erosion: focally stripped; 5.3 Unequivocal erosion; 5.4 Ulcer or granulation tissue |

**Table 2 Simplified Geboes score**

|  |  |
| --- | --- |
| **Simplified Geboes score** |  |
| Grade 0: No inflammatory activity | 0.0 No abnormalities; 0.1 Presence of architectural changes; 0.2 Presence of architectural changes and chronic mononuclear cell infiltrate |
| Grade 1: Basal plasma cells | 1.0 No increase; 1.1 Mild increase; 1.2 Marked increase |
| Grade 2A: Eosinophils in lamina propria | 2A.0 No increase; 2A.1 Mild increase; 2A.2 Marked increase |
| Grade 2B: Neutrophils in lamina propria | 2B.0 No increase; 2B.1 Mild increase; 2B.2 Marked increase |
| Grade 3: Neutrophils in epithelium | 3.0 None; 3.1 < 50% crypts involved; 3.2 > 50% crypts involved |
| Grade 4: Epithelial injury (in crypt and surface epithelium) | 4.0 None; 4.1 Marked attenuation; 4.2 Probable crypt destruction: probable erosions; 4.3 Unequivocal crypt destruction: unequivocal erosion; 4.4 Ulcer or granulation tissue |

**Table 3 Robarts histopathology index**

|  |  |
| --- | --- |
| **Histopathological variable** | **Grade** |
| Chronic inflammatory infiltrate | 0 = No increase; 1 = Mild but unequivocal increase; 2 = Moderate increase; 3 = Marked increase |
| Lamina propria neutrophils | 0 = None; 1 = Mild but unequivocal increase; 2 = Moderate increase; 3 = Marked increase |
| Neutrophils in epithelium | 0 = None; 1 = 50% crypts involved |
| Erosion or ulceration | 0 = No erosion, ulceration or granulation tissue; 1 = Recovering epithelium + adjacent inflammation; 2 = Probable erosion-focally stripped; 3 = Unequivocal erosion; 4 = Ulcer or granulation tissue |

**Table 4 Nancy histological index**

|  |  |
| --- | --- |
| **Grade** | **Criteria** |
| Grade 0 (no histological significant disease) | No or mild increase in chronic inflammatory infiltrate |
| Grade 1 (chronic inflammatory infiltrate with no acute inflammatory infiltrate) | Moderate or marked increase in chronic inflammatory infiltrate that is easily apparent. No acute inflammatory infiltrate is present |
| Grade 2 (mildly active disease) | Few or rare neutrophils in lamina propria or in the epithelium that are difficult to see |
| Grade 3 (moderately active disease) | Presence of multiple clusters of neutrophils in lamina propria and/or in epithelium that are easily apparent |
| Grade 4 (severely active disease) | Loss of colonic crypts replaced with “immature” granulation tissue (disorganized blood vessels with extravasated neutrophils) or the presence of fibrinopurulent exudate |

**Table 5 Global Histology Activity Score**

|  |  |
| --- | --- |
| **Histopathological variable** | **Grade** |
| Epithelial damage | 0 = Normal; 1 = Focal; 2 = Extensive |
| Architectural changes | 0 = Normal; 1 = Moderate; 2 = Severe |
| Mononuclear cells in lamina propria | 0 = Normal; 1 = Moderate increase; 2 = Severe increase |
| Neutrophils in lamina propria | 0 = Normal; 1 = Moderate increase; 2 = Severe increase |
| Neutrophils in epithelium | 1 = Surface epithelium; 2 = Cryptitis; 3 = Crypt abscess |
| Erosion or ulceration | 0 = No; 1 = Yes |
| Granuloma | 0 = No; 1 = Yes |
| Number of segmental biopsy specimens affected | 1 = < 1/3; 2 = 1/3-2/3; 3 = > 2/3 |

Each variable is scored independently. The total score is the sum of all individual scores.

**Table 6 Inflammatory Bowel Disease-Distribution, Chronicity, Activity score**

|  |  |
| --- | --- |
| **Histopathological variable** | **Grade** |
| Distribution | 0 = Normal; 1 = < 50% of tissue affected per same biopsy site; 2 = > 50% of tissue affected per same biopsy |
| Chronicity | 0 = Normal; 1 = Crypt distortion and/or mild lymphoplasmacytosis; 2 = Marked lymphoplasmacytosis and/or basal plasmacytosis |
| Activity | 0 = Normal; 1 = Two or more neutrophils in lamina propria in one high-power field and/or any presence of intraepithelial neutrophils; 2 = Crypt abscesses, erosions, ulcers |

Each variable is scored independently.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**